ARMP Valuation

Armata Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.430

-0.08(-3.187%)1D

Overview
Forecast
Valuation
Earnings

ARMP Relative Valuation

ARMP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARMP is overvalued; if below, it's undervalued.

Historical Valuation

Armata Pharmaceuticals Inc (ARMP) is now in the Fair zone, suggesting that its current forward PS ratio of 17.19 is considered Fairly compared with the five-year average of -3.02. The fair price of Armata Pharmaceuticals Inc (ARMP) is between 1.73 to 2.60 according to relative valuation methord.

Relative Value

Fair Zone

1.73-2.60

Current Price：2.59

Fair

-1.72

Trailing

Forward

-6.53

EV/EBITDA

Armata Pharmaceuticals Inc. (ARMP) has a current EV/EBITDA of -6.53. The 5-year average EV/EBITDA is -2.92. The thresholds are as follows: Strongly Undervalued below -6.37, Undervalued between -6.37 and -4.64, Fairly Valued between -1.19 and -4.64, Overvalued between -1.19 and 0.54, and Strongly Overvalued above 0.54. The current Forward EV/EBITDA of -6.53 falls within the Strongly Undervalued range.

-6.53

EV/EBIT

Armata Pharmaceuticals Inc. (ARMP) has a current EV/EBIT of -6.53. The 5-year average EV/EBIT is -3.70. The thresholds are as follows: Strongly Undervalued below -6.07, Undervalued between -6.07 and -4.89, Fairly Valued between -2.52 and -4.89, Overvalued between -2.52 and -1.34, and Strongly Overvalued above -1.34. The current Forward EV/EBIT of -6.53 falls within the Strongly Undervalued range.

16.73

Armata Pharmaceuticals Inc. (ARMP) has a current PS of 16.73. The 5-year average PS is 36.28. The thresholds are as follows: Strongly Undervalued below -85.47, Undervalued between -85.47 and -24.60, Fairly Valued between 97.16 and -24.60, Overvalued between 97.16 and 158.03, and Strongly Overvalued above 158.03. The current Forward PS of 16.73 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Armata Pharmaceuticals Inc. (ARMP) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

-10.93

P/FCF

Armata Pharmaceuticals Inc. (ARMP) has a current P/FCF of -10.93. The 5-year average P/FCF is -1.26. The thresholds are as follows: Strongly Undervalued below -6.24, Undervalued between -6.24 and -3.75, Fairly Valued between 1.22 and -3.75, Overvalued between 1.22 and 3.71, and Strongly Overvalued above 3.71. The current Forward P/FCF of -10.93 falls within the Strongly Undervalued range.

Armata Pharmaceuticals Inc (ARMP) has a current Price-to-Book (P/B) ratio of -1.32. Compared to its 3-year average P/B ratio of -0.55 , the current P/B ratio is approximately 142.31% higher. Relative to its 5-year average P/B ratio of 1.12, the current P/B ratio is about -218.41% higher. Armata Pharmaceuticals Inc (ARMP) has a Forward Free Cash Flow (FCF) yield of approximately -33.94%. Compared to its 3-year average FCF yield of -54.92%, the current FCF yield is approximately -38.21% lower. Relative to its 5-year average FCF yield of -40.95% , the current FCF yield is about -17.12% lower.

-1.31

P/B

Median3y

-0.55

Median5y

1.12

-34.87

FCF Yield

Median3y

-54.92

Median5y

-40.95

Competitors Valuation Multiple

The average P/S ratio for ARMP's competitors is 11.55, providing a benchmark for relative valuation. Armata Pharmaceuticals Inc Corp (ARMP) exhibits a P/S ratio of 16.73, which is 44.91% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARMP.A

Armata Pharmaceuticals Inc

Immunoprecise Antibodies Ltd

Quince Therapeutics Inc

Loss

86.48M

NAUT.O

Nautilus Biotechnology Inc

Loss

84.40M

CSBR.O

Champions Oncology Inc

Pliant Therapeutics Inc

45.12

89.01M

Performance Decomposition

Market capitalization of ARMP decreased by 0.82% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 2.17M.

The secondary factor is the Margin Expansion, contributed -54.74%to the performance.

Overall, the performance of ARMP in the past 1 year is driven by Revenue Growth. Which is more sustainable.

NaN%

0.00 → 2.17M

Revenue Growth

-54.74%

-1.66K → -751.27

Margin Expansion

NaN%

0.00 → -1.86

P/E Change

-0.82%